|Podcasts|September 16, 2021
Episode 91: A New Way to Partner With Academia
Author(s)Elaine Quilici, Miranda Schmalfuhs
Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.
Advertisement
Dr. Michael Henderson, Chief Business Officer of BridgeBio Pharma, talks about how his company is partnering with academia in a novel way to develop important programs that might otherwise be dropped.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Nimbus Therapeutics and Eli Lilly Enter $1.3 Billion License Agreement and Research Collaboration for Oral Obesity Treatments
2
Amgen Acquires Dark Blue Therapeutics in $840 Million Transaction
3
Novo Nordisk’s Wegovy Pill Becomes First Oral GLP-1 Available in U.S.
4
The Real Value Equation: How Humans and AI Create and Destroy Value in Pharma
5